Thoracic Imaging

What Is the Best Imaging for Staging Non–Small-Cell Lung Carcinoma?

·
What Is the Best Imaging for Staging Non–Small-Cell Lung Carcinoma?

A 68-year-old man with a 40-pack-year smoking history presents with a persistent cough. A chest radiograph reveals a right upper lobe mass, and subsequent bronchoscopy with biopsy confirms non–small-cell lung carcinoma (NSCLC). You are now tasked with the crucial next step: initial clinical staging to determine the extent of disease and guide therapy. The patient is asymptomatic from a neurologic perspective. The core question is how to comprehensively and accurately assess for distant metastases, particularly to the brain, adrenal glands, and bone, before committing to a treatment plan. For evaluating the brain, the American College of Radiology (ACR) Appropriateness Criteria rate `MRI head without and with IV contrast` as Usually appropriate.

## Who Fits This Clinical Scenario?

This guidance applies specifically to patients with a new, biopsy-proven diagnosis of non–small-cell lung carcinoma (NSCLC) who require initial, noninvasive clinical staging before the initiation of therapy. The goal is to establish the baseline tumor (T), nodal (N), and metastasis (M) stage, which is fundamental to determining prognosis and selecting the optimal treatment strategy, whether it be surgical resection, definitive chemoradiation, or systemic therapy.

This workflow is distinct from several related but different clinical situations:

  • Small-Cell Lung Carcinoma (SCLC): Patients diagnosed with SCLC follow a different staging and treatment paradigm due to the tumor’s distinct biology and typical early dissemination. This scenario is covered in a separate ACR variant.
  • Undiagnosed Solitary Pulmonary Nodule: An incidental or symptomatic lung nodule without a tissue diagnosis falls under different guidelines, such as Lung-RADS, focused on characterization and determining the need for biopsy, not systemic staging.
  • Post-Treatment Restaging or Surveillance: This guidance does not apply to patients who have already undergone treatment for NSCLC and are now being evaluated for recurrence or response to therapy.

## What Diagnoses Are You Working Up in This Scenario?

While the primary diagnosis of NSCLC is established, the purpose of staging is to systematically search for metastatic disease. The imaging workup is designed to interrogate the most common sites of distant spread, as the presence of metastases (M1 disease) classifies the cancer as Stage IV and fundamentally alters the treatment approach from curative-intent to palliative-intent systemic therapy.

Brain Metastases: The brain is a frequent site of metastasis for NSCLC, even in neurologically asymptomatic patients. Identifying brain lesions is critical because they can significantly impact prognosis and require specific local therapies like stereotactic radiosurgery (SRS) or whole-brain radiation therapy (WBRT) in addition to systemic treatment.

Mediastinal and Hilar Lymph Node Metastases: Accurate N-staging is paramount for determining surgical candidacy. The presence and location of involved lymph nodes (N1, N2, or N3 disease) dictate whether a patient is a candidate for surgical resection, neoadjuvant therapy, or definitive chemoradiation.

Distant Extrathoracic Metastases: NSCLC commonly spreads to the adrenal glands, liver, and bones. Identifying metastases in these locations confirms Stage IV disease. Adrenal metastases can sometimes be difficult to distinguish from benign adenomas without advanced imaging techniques. Bone metastases can lead to pathologic fractures and significant pain, requiring palliative radiation or bone-stabilizing procedures.

## Why Is a Comprehensive Staging Workup Recommended for This Presentation?

For the initial staging of NSCLC, the ACR designates four studies as Usually appropriate: `FDG-PET/CT skull base to mid-thigh`, `CT chest with IV contrast`, `CT chest without IV contrast`, and `MRI head without and with IV contrast`. While PET/CT and chest CT are foundational for evaluating the primary tumor, lymph nodes, and extracranial sites, dedicated brain imaging with MRI plays a unique and critical role.

Rationale for Dedicated Brain MRI:
`MRI head without and with IV contrast` is considered the most sensitive noninvasive test for detecting brain metastases. Its superiority over other modalities stems from its exceptional soft tissue contrast, which allows for the identification of small parenchymal lesions, leptomeningeal disease, and posterior fossa abnormalities that can be obscured on CT by beam-hardening artifact. The combination of non-contrast sequences (to detect hemorrhage) and post-contrast sequences (to highlight enhancing tumor deposits) provides a comprehensive evaluation. Importantly, this study involves no ionizing radiation (0 mSv).

Comparison to Alternatives:

  • FDG-PET/CT: While `FDG-PET/CT skull base to mid-thigh` is also rated Usually appropriate and is excellent for identifying metabolically active disease in the chest and abdomen, it is less sensitive than MRI for detecting brain metastases. The high baseline glucose metabolism of normal brain tissue can mask small or non-avid metastatic deposits, leading to false negatives.
  • CT Head: A `CT head with IV contrast` is rated lower as May be appropriate. It is less sensitive than MRI, particularly for metastases smaller than 1 cm, and for lesions located near the skull base or in the posterior fossa. It is often reserved for patients with contraindications to MRI.
  • Bone Scan: A `Bone scan whole body` is rated May be appropriate but has largely been supplanted by the superior sensitivity and specificity of FDG-PET/CT for detecting osseous metastases from NSCLC.

In modern practice, comprehensive staging for a potentially curable NSCLC patient often involves both an FDG-PET/CT for systemic evaluation and a dedicated brain MRI for CNS evaluation, as they provide complementary information essential for accurate T, N, and M staging.

## What’s Next After Staging? Downstream Workflow

The results of the complete noninvasive staging workup directly guide the multidisciplinary tumor board discussion and subsequent treatment decisions.

  • If Staging Reveals Early-Stage Disease (e.g., Stage I-II): If the FDG-PET/CT shows no evidence of nodal or distant metastatic disease, and the brain MRI is negative, the patient is likely a candidate for curative-intent therapy. This typically involves surgical resection (lobectomy) followed by adjuvant chemotherapy, depending on the final pathologic stage.
  • If Staging Reveals Locally Advanced Disease (e.g., Stage III): If imaging identifies extensive mediastinal lymph node involvement (N2/N3 disease) but no distant metastases, the patient is generally not a primary surgical candidate. The standard of care is often concurrent chemoradiation, potentially followed by immunotherapy. Invasive mediastinal staging (e.g., EBUS/EUS) is typically required to confirm nodal involvement seen on imaging before committing to non-surgical treatment.
  • If Staging Reveals Metastatic Disease (Stage IV): If the brain MRI or PET/CT identifies distant metastases, the treatment intent shifts from curative to palliative. The primary treatment is systemic therapy (chemotherapy, targeted therapy based on molecular markers, or immunotherapy). Local treatments, such as radiation to the brain or a painful bone lesion, are used for symptom control.

## Pitfalls to Avoid (and When to Get Help)

Accurate initial staging is a high-stakes process where errors can lead to suboptimal treatment. Key pitfalls to avoid include:

  • Omitting Brain Imaging: Relying solely on a negative neurologic exam to exclude brain metastases is a common error. A significant portion of patients with brain metastases are asymptomatic at diagnosis.
  • Relying on PET/CT for Brain Staging: Assuming a PET/CT of the whole body provides adequate evaluation of the brain can lead to missed CNS metastases. Dedicated brain MRI is the standard.
  • Incomplete Nodal Evaluation: For patients with suspected mediastinal node involvement on CT or PET/CT, proceeding directly to surgery without pathologic confirmation (e.g., via EBUS) can result in an incomplete resection.
  • Misinterpreting Adrenal Nodules: An adrenal nodule seen on CT or PET/CT is not definitively metastatic. It may be a benign adenoma, requiring further characterization with adrenal-protocol CT or MRI if it will change management.

If staging results are complex or equivocal, discussion at a multidisciplinary thoracic oncology conference is the standard of care to ensure all therapeutic options are considered.

## Related ACR Topics and Tools

This article covers one specific scenario within the broader topic of lung cancer staging. For a comprehensive overview of all related clinical variants, please consult the parent guide. The following GigHz resources can also support your clinical workflow:

Frequently Asked Questions

Is a brain MRI necessary for every new diagnosis of non–small-cell lung carcinoma?

For most patients, especially those with adenocarcinoma histology or those being considered for curative-intent therapy (Stage I-III), dedicated brain imaging is recommended regardless of neurologic symptoms. Brain metastases are common and their presence fundamentally changes the stage and treatment plan. Guidelines from organizations like the NCCN recommend brain MRI as part of the initial workup for stages IB-IV.

Can I just order a PET/CT and a contrast-enhanced chest CT instead of all four ‘Usually Appropriate’ studies?

In many centers, the standard workup for a potentially resectable NSCLC is an FDG-PET/CT and a dedicated brain MRI. A diagnostic-quality contrast-enhanced chest CT is often performed as part of the PET/CT, providing the necessary anatomic detail of the primary tumor and its relationship to adjacent structures. A non-contrast chest CT is less common as a standalone staging study but may be used if IV contrast is contraindicated.

What if my patient has a contraindication to MRI, like a non-compatible pacemaker?

If a patient cannot undergo an MRI, the next best alternative for brain evaluation is a `CT head with IV contrast`. While it is rated as May be appropriate and is less sensitive than MRI for small lesions, it is the standard alternative in this situation. It is crucial to use intravenous contrast to maximize the detection of enhancing metastatic deposits.

Why is a plain chest radiograph rated ‘Usually not appropriate’ for staging?

While a chest radiograph may have been the initial test that detected the lung mass, it is inadequate for staging. It has very low sensitivity for identifying mediastinal lymph node involvement, small pleural effusions, or subtle satellite nodules. Cross-sectional imaging with CT and/or PET/CT is required for accurate T and N staging.

Does the histology of the NSCLC (e.g., adenocarcinoma vs. squamous cell) affect the choice of staging imaging?

While the general staging principles apply to all NSCLC histologies, there are some differences in metastatic patterns. For instance, adenocarcinoma has a higher propensity for brain metastases than squamous cell carcinoma. This reinforces the importance of dedicated brain MRI, particularly in patients with adenocarcinoma, even if they are early stage by chest imaging.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 26, 2026